Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

被引:78
作者
Kyle, Robert A. [1 ]
Rajkumar, S. Vincent [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
关键词
monoclonal gammopathy of undetermined significance; multiple myeloma; macroglobulinaemia; smouldering multiple myeloma;
D O I
10.1111/j.1365-2141.2007.06873.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein < 30 g/l, < 10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions). MGUS is present in 3% of persons > 50 years and in 5% > 70 years of age. The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year. Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein >= 15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present. Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage. The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years.
引用
收藏
页码:730 / 743
页数:14
相关论文
共 86 条
[11]   MALIGNANT TRANSFORMATION AND LIFE EXPECTANCY IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE [J].
BLADE, J ;
LOPEZGUILLERMO, A ;
ROZMAN, C ;
CERVANTES, F ;
SALGADO, C ;
AGUILAR, JL ;
VIVESCORRONS, JL ;
MONTSERRAT, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) :391-394
[12]   IGD MONOCLONAL GAMMOPATHY WITH LONG-TERM FOLLOW-UP [J].
BLADE, J ;
KYLE, RA .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (02) :395-396
[13]   Clinical practice:: Monoclonal gammopathy of undetermined significance [J].
Blade, Joan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2765-2770
[14]  
Cesana A, 2005, CLIN LYMPHOMA, V5, P261
[15]   Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma [J].
Cesana, C ;
Klersy, C ;
Barbarano, L ;
Nosari, AM ;
Crugnola, M ;
Pungolino, E ;
Gargantini, L ;
Granata, S ;
Valentini, M ;
Morra, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1625-1634
[16]   A validated FISH trisony index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS [J].
Chng, WJ ;
Van Wier, SA ;
Ahmann, GJ ;
Winkler, JM ;
Jalal, SM ;
Bergsagel, PL ;
Chesi, M ;
Trendle, MC ;
Oken, MM ;
Blood, E ;
Henderson, K ;
Santana-Dávila, R ;
Kyle, RA ;
Gertz, MA ;
Lacy, MQ ;
Dispenzieri, A ;
Greipp, PR ;
Fonseca, R .
BLOOD, 2005, 106 (06) :2156-2161
[17]   Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].
Croucher, PI ;
Shipman, CM ;
Lippitt, J ;
Perry, M ;
Asosingh, K ;
Hijzen, A ;
Brabbs, AC ;
van Beek, EJR ;
Holen, I ;
Skerry, TM ;
Dunstan, CR ;
Russell, GR ;
Van Camp, B ;
Vanderkerken, K .
BLOOD, 2001, 98 (13) :3534-3540
[18]   Monoclonal gammopathies and associated skin disorders [J].
Daoud, MS ;
Lust, JA ;
Kyle, RA ;
Pittelkow, MR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (04) :507-538
[19]   RISK OF DISEASE PROGRESSION IN ASYMPTOMATIC MULTIPLE-MYELOMA [J].
DIMOPOULOS, MA ;
MOULOPOULOS, A ;
SMITH, T ;
DELASALLE, KB ;
ALEXANIAN, R .
AMERICAN JOURNAL OF MEDICINE, 1993, 94 (01) :57-61
[20]   Focal and segmental glomerulosclerosis and plasma cell proliferative disorders [J].
Dingli, D ;
Larson, DR ;
Plevak, MF ;
Grande, JP ;
Kyle, RA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (02) :278-282